等待開盤 03-26 09:30:00 美东时间
+0.310
+1.21%
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 19 (Reuters) - Wall Street's main indexes were set to open lower on
03-19 21:15
BUZZ-Greenwich LifeSciences rises after expanding late‑stage breast cancer trial ** Shares of biotech firm Greenwich LifeSciences GLSI.O rise about 1.1% to $27 premarket ** Co says it has expanded its late‑stage trial of GLSI‑100, an experimental treatment aimed at preventing breast cancer recurrenc
03-19 18:50
Greenwich LifeSciences, Inc. announced updates on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences. Two abstracts and posters were accepted for presentation at the AACR Annual Meeting 2026, focusing on immune response data and trial design. GLSI-100 has shown a 70-80% reduction in recurrence rates in early analysis. The trial, led by prominent oncologists and researchers, is...
03-18 10:00
BUZZ-U.S. STOCKS ON THE MOVE-Uber, Honeywell, Delta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 17 (Reuters) - U.S. stock index futures slipped on Tuesday as the Middle
03-17 19:42
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is
03-16 18:12
Greenwich LifeSciences announced that commercially manufactured GP2 for its FLAMINGO-01 Phase III breast cancer prevention trial has been approved by the FDA and distributed to all 40 U.S. sites. CEO Snehal Patel highlighted plans to expand production capacity to 500,000–1 million vials annually. The trial has enrolled over 1,000 patients, with a non-HLA-A*02 arm fully enrolled, showing an 80% reduction in recurrence rates after the Primary Immun...
03-16 10:00
Greenwich LifeSciences shares are trading higher after the company announced th...
02-25 00:35
Greenwich LifeSciences announced that two abstracts have been accepted for presentation at the AACR 2026 Annual Meeting. The FLAMINGO-01 Phase III trial evaluates GLSI-100, an immunotherapy for preventing breast cancer recurrences. Initial data from the trial shows an approximately 80% reduction in recurrence rates in the non-HLA-A*02 arm, aligning with Phase IIb results. The AACR meeting will occur April 17-22, 2026, with abstracts published on ...
02-24 11:00
Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driv...
01-30 23:36
BNAI飙涨276%,公司布局非洲人工智能市场;LE大涨33%,与WHP Global成立合资公司,释放品牌价值;坦桑尼亚黄金涨超21%,金价延续强势震荡走高>>
01-27 20:05